Blog

Tirzepatide Compounding Update

Posted by Jason Balogh | Jan 23, 2025 | 0 Comments

The FDA has stated that it does not intend to take action against compounders for violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) arising from conditions 
that depend on tirzepatide's inclusion on the FDA drug shortage list. Compounding pharmacies should still exercise their own best judgment as individual State Boards may still decide to take action against a compounder licensed in their state. 

Further, compounders should be aware that this does not insulate compounders from FDA action for violations unrelated to tirzepatide's inclusion the shortage list, such as those for substandard or unsafe products.

About the Author

Comments

There are no comments for this post. Be the first and Add your Comment below.

Leave a Comment

Balogh Law Ltd. Is Here for You

Balogh Law Ltd. focuses on Real Estate Litigation, Professional Malpractice, Outside General Counsel Services, Business Formation, Administrative & Regulatory, Professional Licensing, Pharmacy & Pharmacist Defense, Personal Injury, and Employment Law.

Contact Us Today

We offer consultations and we'll gladly discuss your case with you at your convenience. Contact us today to schedule an appointment.

Virtual Office

Based in the San Francisco Bay Area
925-575-8056